Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Aakriti Gupta

Interventional Cardiology Los Angeles, CA Medical Doctor

NPI 1477998995 CMS profile 8801768

127 S San Vicente Blvd Ste A3600, Los Angeles, CA 90048

Open in the dashboard

General payments

$138,692

736 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aakriti Gupta of Los Angeles, CA is reported in the CMS Open Payments database as having received $138,692 across 736 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $31,222 139
2024 General $12,176 164
2023 General $7,048 148
2022 General $8,387 191
2021 General $77,122 89
2020 General $2,738 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aakriti Gupta
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Aakriti Gupta were reported at $31,222. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Aakriti Gupta Interventional Cardiology median Middle half National median
2019 $0 $1,097 $329–$3,048 $163
2020 $2,738 $473 $161–$1,480 $114
2021 $77,122 $677 $233–$1,827 $132
2022 $8,387 $978 $333–$2,724 $149
2023 $7,048 $1,136 $382–$2,986 $160
2024 $12,176 $1,181 $395–$3,326 $164
2025 $31,222 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Boston Scientific Corporation $55,093 41 payments
  2. Edwards Lifesciences Corporation $51,601 593 payments
  3. Medtronic, Inc. $17,927 11 payments
  4. Abbott Laboratories $7,897 39 payments
  5. Shockwave Medical, Inc $2,555 3 payments
  6. Abiomed $1,909 27 payments
  7. Cardiovascular Systems Inc. $571 4 payments
  8. Penumbra, Inc. $235 1 payment
  9. HeartFlow, Inc. $229 5 payments
  10. Teleflex LLC $146 1 payment
  11. Other $530 11 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Grant $73,000 4 payments
  2. Food and Beverage $32,944 711 payments
  3. Travel and Lodging $16,006 14 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,420 2 payments
  5. Consulting Fee $7,040 3 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $2,200 1 payment
  7. Education $82 1 payment
Products named General payments · program years 2020–2025
  1. GENERAL STRUCTURAL HEART $50,000 1 payment
  2. CoreValve Evolut $17,000 1 payment
  3. SAPIEN 3 Ultra RESILIA $16,291 334 payments
  4. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $13,049 60 payments
  5. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $4,997 174 payments
  6. MitraClip System $4,656 5 payments
  7. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $2,555 3 payments
  8. Impella $1,882 26 payments
  9. Dragonfly OCT $1,500 1 payment
  10. COREVALVE EVOLUT R $883 9 payments
  11. Other $5,657 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

13

Median for Interventional Cardiology: 2,236

Drug cost

$239

Median for Interventional Cardiology: $380,412

Branded share of claims

100%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 13 $239

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$64,991

Medicare's payments for the services billed

Medicare patients

171

Average age 75

Services billed

285

72 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 75%
Diabetes 57%
Atrial fibrillation 56%
Arthritis 56%
Chronic kidney disease 49%
COPD 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

736 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record